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Abstract
Background: Tuberculosis (TB) is an enduring health problem worldwide and the emerging threat of multidrug
resistant (MDR) TB and extensively drug resistant (XDR) TB is of particular concern. A better understanding of
biomarkers associated with TB will aid to guide the development of better targets for TB diagnosis and for the
development of improved TB vaccines.
Methods: Recombinant proteins (n = 7) and peptide pools (n = 14) from M. tuberculosis (M.tb) antigens associated
with M.tb pathogenicity, modification of cell lipids or cellular metabolism, were used to compare T cell immune
responses defined by IFN-g production using a whole blood assay (WBA) from i) patients with TB, ii) individuals
recovered from TB and iii) individuals exposed to TB without evidence of clinical TB infection from Minsk, Belarus.
Results: We identified differences in M.tb target peptide recognition between the test groups, i.e. a frequent
recognition of antigens associated with lipid metabolism, e.g. cyclopropane fatty acyl phospholipid synthase. The
pattern of peptide recognition was broader in blood from healthy individuals and those recovered from TB as
compared to individuals suffering from pulmonary TB. Detection of biologically relevant M.tb targets was confirmed
by staining for intracellular cytokines (IL-2, TNF-a and IFN-g) in T cells from non-human primates (NHPs) after BCG
vaccination.
Conclusions: PBMCs from healthy individuals and those recovered from TB recognized a broader spectrum of M.tb
antigens as compared to patients with TB. The nature of the pattern recognition of a broad panel of M.tb antigens
will devise better strategies to identify improved diagnostics gauging previous exposure to M.tb; it may also guide
the development of improved TB-vaccines.
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Background
Tuberculosis (TB) is one of the major global health
issue, and a serious health concern in Belarus where the
prevalence and spread of multidrug-resistant (MDR) TB
and extensively drug resistant (XDR) TB has increased
during the last few years. About 5000 individuals are
newly diagnosed each year in Belarus and the prevalence
of TB is 52/100,000 individuals [1]. A recent study iden-
tified MDR TB in 35.3% of newly diagnosed patients
and in 76.5% of individuals who have previously been
treated. XDR TB could be identified in 14.0% among
the patients diagnosed with MDR TB [2]; these are
alarming levels of resistant TB in Belarus.
Early diagnosis of the disease and the rapid identifica-
tion of resistance to primary anti-TB drugs are essential
for efficient treatment, prevention and control of TB.
The diagnosis of TB in many countries, including
Belarus, still relies on the tuberculin skin test (TST) and
direct sputum examination by light microscopy. The
TST has low specificity due to cross-reactivity to protein
purified derivative (PPD) antigens shared by environ-
mental mycobacteria species, and may give false positive
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individuals. BCG policies vary considerably between
countries, primarily depending on the current epidemio-
logical situation. Individuals in Belarus, as well as in
Russia may be vaccinated three times with BCG; the pat-
tern of cellular immune responses and antigen recogni-
tion after several BCG vaccinations has not been
analyzed in detail up to now. BCG vaccination takes
place early in life, BCG re-vaccination takes place during
school years, a third vaccination is considered based on
tuberculin skin tests (TST); BCG re-vaccination may
also be postponed in adults (up to 30 years) in areas of
low TB prevalence [3,4].
Interferon-g release assays (IGRAs) have been
designed to overcome the problem of cross-reactive T
cell immune responses by measuring immune responses
to antigens specific for M. tuberculosis (M.tb). Quanti-
FERON-TB Gold In-tube (QFT-GIT) [5] measures INF-
g release by sensitized T cells after stimulation with pep-
tides from the early secreted antigenic target 6 (ESAT-
6), culture filtrate protein-10 (CFP-10) and TB-7.7
which are absent in BCG and in most environmental
mycobacteria [6,7]. Neither the TST nor the QTF-GIT,
however, is able to discriminate between active TB-dis-
ease, latent TB-infection (LTBI) and previous TB-infec-
tion. Exposure to Mycobacteria other than tuberculosis
(MOTT) may lead to false-positive results, and poor
specificity of the tests may lead to unnecessary prophy-
lactic treatment with anti-tuberculosis drugs. Thus, the
ideal diagnostic test should not only discriminate LTBI
from active TB, but also discriminate between TB,
MOTT and previous BCG vaccination. This is of parti-
cular concern in Belarus since TB treatment can be trig-
g e r e db yap o s i t i v eT S T .I nc o n t r a s t ,an e g a t i v eT S T
may lead to repeated BCG vaccination according to
national guidelines, since TST diameter is also used to
gauge treatment responses, in addition to standard clini-
cal and microbiological evaluation.
Although LTBI is clinically silent and not contagious,
it can reactivate to cause contagious pulmonary TB [8].
Tubercle bacilli are generally considered to be non-
replicating in LTBI, yet it may slowly grow and replicate
[9]. LTBI is characterized by highly reduced bacterial
metabolism and a significantly altered gene expression
[10-12] associated with the different stages of infection
[13-15]. Since most cases of active TB arise in people
with LTBI, there is an urgent need to identify new
potential targets for TB diagnosis and for the develop-
ment of an improved TB vaccine.
One of the strategies in developing new diagnostic
methods and in improving the TB vaccine involves the
identification of epitopes in antigens that induce T cell
responses. We have previously scanned 61 proteins from
M.tb proteome, which facilitated the identification of
potential targets to elicit T cell responses, and showed
that there is a difference in peptide recognition pattern
between M.tb-infected patients and healthy controls
[16,17]. Some of these peptides were also tested for
binding to the most frequent Caucasian and African
MHC Class II alleles (HLA-DRB1*0101, DRB1*1501 and
DRB1*0401) in different populations [17], they may
serve as potential strong B and also T cell targets. The
aim of this study was to compare T cell responses and
INF-g production to these candidate proteins associated
with different stages of M.tb infection, expressed by
replicating versus non-replicating bacteria.
Methods
Study population
The study population consists of 45 individuals from
Belarus (vaccinated three times with BCG) and 17 indivi-
duals from Sweden (who did not receive BCG vaccina-
tion). The following individuals were enrolled from
Belarus: i) individuals with active pulmonary TB (n = 15)
were recruited from the Research Institute for Pulmonol-
ogy and Tuberculosis in Minsk. TB diagnosis was based
on patient history, chest X-ray and TST, confirmed by
positive acid fast staining (AFS) and subsequent culture
(MGIT system). The detailed characteristics of the study
population are provided in the Additional file 1: Table
S1. The mean age was 39 years, 60% males and 40%
females ii) individuals with previous pulmonary TB (n =
15), mean age 40 years, 0% males, 100% females, all had
drug-susceptible TB) and iii) clinically healthy individuals
(n = 15) with no symptoms of TB at the time of sample
collection (mean age 42 years, 20% males, 80% females).
These ‘healthy individuals’ were health care workers and
laboratory staff, and many of them had most likely been
exposed to M.tb. All subjects included in this study were
HIV negative. The current health care policies, diagnostic
steps and TB treatment protocols have been recently
r e v i e w e da n dr e p o r t e df o rB e l a r u s[ 2 ] .I n f o r m e dc o n s e n t
was obtained from all the subjects and the study was
approved by the Local Research Ethics Committee of
Belarus (No. 3, 22.07.2008). Individuals from Sweden
provided informed consent; their mean age was 20 years
(29% males, 71% females, immune cells analysis for M.tb
-associated target antigens was approved by the Ethics
Committee in Stockholm, Sweden; diary number 2011/
863-31/2), all individuals from Sweden tested negative in
the QFT-GIT test.
TST, AFS and culture
The Mantoux skin test (TST) (Biolek, Kharkov, Ukraine)
was used as a standard method for the diagnosis of TB/
LTBI. The skin reaction was read after 3 days by mea-
suring the transverse diameter of induration in mm.
The classification of tuberculin reaction was: negative
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result = any size of hyperemia or papula up to 5 mm;
positive reaction = papule or infiltrate from 5 to 21 mm.
This readout is according to the Belarus national stan-
dard criteria. Sputum was obtained from each TB-
patient and acid -fast bacilli were detected by direct
microscopy. The positive results in acid-fast-staining
(AFS) were confirmed by culture using the BACTEC
MGIT 960 (Becton Dickinson, Franklin Lakes, NJ, USA).
QuantiFERON-TB gold in-tube (QTF-GIT)
The QFT-GIT test was performed according to the manu-
facturer’s instructions (Cellestis, Copenhagen, Denmark).
In brief, 1 ml of blood was drawn directly into vacutainer
tubes, either pre-coated with saline (negative control), pep-
tides from ESAT-6, CFP-10 and TB-7.7 or PHA (mitogen
control). Tubes were incubated for 18-20 hours at 37°C in
CO2 5% and supernatants were harvested and the amount
of IFN-g produced was measured by ELISA.
M.tb-antigens
Synthetic 15-mer peptide pools were generated (JPT
Peptide Technologies, Berlin, Germany) which have
been found to bind to MHC class II molecules. The
respective protein and peptide targets are listed in Table
1 and the individual peptide sequences are provided in
the Additional file 2: Table S2. The recombinant pro-
teins Rv3804c (Ag85A), Rv1886c (Ag85B) and Rv0288
(TB10.4) and peptide pools from Rv0959 (Ag85A/B) and
Rv0288 (TB10.4) were kindly provided by the AERAS
Global TB Foundation (AERAS, Washington DC, US).
Recombinant ESAT-6 (Rv3875) was purchased from Sta-
tens Serum Institute (SSI, Copenhagen, Denmark).
Recombinant PPE-proteins Rv0754, Rv0978c and
Rv1917c [18-21] were provided by K. N. Balaji, Banga-
lore, India. PHA (Sigma Aldrich, Stockholm, Sweden)
was used as a positive control for IFN-g production.
Whole blood assay (WBA)
The whole-blood assay was performed as described pre-
viously [22,23]. In brief, heparin whole blood was diluted
1:2.5 with serum-free medium (RPMI-1640 supplemen-
ted with 2 mM L-glutamine and penicillin-Streptomycin,
(Invitrogen, Stockholm, Sweden). 100 μl of diluted blood
was plated in duplicates in 96-well, round-bottom tissue
culture plates (Nunc, Roskilde, Denmark) pre-coated
with 100 μl of the diluted antigens resulting in the final
volume of 200 μl in each well and the final whole blood
dilution of 1:5. Peptides and proteins were used at the
final concentration of 1 μg/ml and 5 μg/ml, respectively.
PHA (5 μg/ml; Sigma Aldrich, Stockholm, Sweden)
served as a positive control and medium diluted whole
blood as a negative control. Cell cultures were incubated
at 37°C with 5% CO2. Supernatants were harvested on
d a y7a n ds t o r e da t- 8 0 ° Cu n t i la n a l y s i s .I F N - g in cell
culture supernatants was determined by a commercially
available ELISA assay following the manufactures
instructions (IFN-g Eli-pair, Biosite, Stockholm, Sweden).
The detection limit of the assay was 6.5 pg/ml.
Intracellular cytokine staining (ICS)
PBMCs from non-human primates (NHP) included in
our earlier vaccine studies [24] were stained as described
for ICS [25]. Peripheral blood samples were obtained
from female rhesus macaques (Macaca mulatta)o fC h i -
nese origin with an age range between 3 and 4 years.
Animals were captive bred for research purposes and
housed in the Astrid Fagraeus laboratory at the con-
tained experimental facilities at the Biomedical Primate
Research Centre. The local Ethical Committees
approved all procedures (protocol DNR238/2006-54 and
DEC#551, respectively). PBMCs were isolated from
freshly obtained, heparinized peripheral blood by Ficoll-
Hypaque density gradient centrifugation and processed.
In brief, frozen NHP PBMCs obtained before as well as
after BCG/rBCG vaccination were rested overnight and
stimulated 6 h with PMA/Ionomycin (Sigma-Aldrich,
Stockholm, Sweden) and peptide pools Rv0447c (puta-
tive cyclopropane fatty-acid synthase) and mixture of
Rv2957 and Rv2958c (possible glycosyl transferase) in a
presence of Brefeldin-A (Sigma-Aldrich, Stockholm,
Sweden). Cells were stained for cell surface markers
using anti-CD3-Pacific Blue (SP34-2), CD4-PerCpCy5.5
(L200) and CD8-APCCy7 (SK1). Subsequently, cells
were fixed, permeabilized (IntraPrep Fix/Perm Kit, Beck-
man Coulter, Marseille, France) and stained with anti-
IFN-g-PECy7 (B27), TNF-a-APC and IL-2-PE (MQ1-
17H12) followed by flow cytometric analysis using FAC-
SAria flow cytometer (BD Biosciences, Stockholm, Swe-
den) and FlowJo software (Tree Star Inc., Ashland, OR).
Statistical methods
The mean of the medium controls in IFN-g ELISA plus
2 standard deviations was used as a cut-off value for the
positive results. The multiplicity problem introduced by
using different antigens and by comparing different
groups was corrected by method for False-discovery rate
(FDR). All p-values reported are adjusted with FDR.
Fisher’s exact test was used to determine the association
between the outcome of each immunological measure-
ment and different patient groups, and for comparison
of the proportion of responders in each group. Statistical
analyses were performed in R v2.11.0
Results
TST, AFS and isolation of viable bacteria
Results of TST, AFS and culture are shown in Tables 2
and 3, the detailed clinical and microbiological data for
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Additional file 1: Table S1. A total of 43/45 (96%) of
individuals tested were TST positive. Fourteen (93%) of
TB patients exhibited a positive TST, including indivi-
duals with negative AFS and/or culture (Table 2), yet
with typical X-ray signs. 11/15 (73%) of patients with
TB tested positive for M.tb culture and 4/15 (27%) were
positive in AFS. TST results of the individuals recovered
from TB and of healthy participants are shown in Table
3. All participants from Sweden were TST negative
(data not shown).
In vitro short-term IFN-g responses to ESAT-6, CFP-10 and
TB7.7
The results of the INF-g production in response to
ESAT-6, CFP-10 and TB7.7 ar es h o w ni nT a b l e s2a n d
3. 11/15 (73%) of TB+ patients, 9/15 (60%) of the indivi-
duals recovered from TB and 6/15 (40%) of healthy
donors showed a positive response in a QTF-GIT test.
In two TB cases, the QTF-GIT exhibited negative
results, although M.tb could be detected by AFS and/or
culture (ID 011-5 and 021-1). The cut-off for positive
results was 0.35 IU/ml above the Nil (negative) control
Table 1 M.tb target antigens used for T cell stimulation
M.tb target protein ID Biology
Cyclopropane fatty acyl phospholipid
synthase
Rv0447c Involved in lipid formation and synthesis of long fatty acids, resistance to (oxidative)
stress and survival
Mycobacterium bovis mycocerosic
acid synthase gene (mas)
Rv2940c (mas) multifunctional enzyme that catalyzes the synthesis of very long chain
multiple methyl branched fatty acids called mycocerosic acids present in slow-
growing pathogenic mycobacteria, major mycobacterial cell wall complex
PPE family proteins Rv3347c Accounts for about 10% of the genomic M.tb coding capacity. Form a source for
antigenic variation among different M.tb strains
Rv1917c (p) Induces functional maturation of dendritic cells through an integrated cross talk
between PI3K-MAPK and NF-B signaling cascades and facilitates a Th2 phenotype
PE_PGRS 11 family proteins Rv0754 (p) Rv0978c
(p)
Cell wall associated protein, induces activation and maturation of human dendritic
cells as well as secretion of key proinflammatory cytokines
Probable molybdopterin-guanine
dinucleotide biosynthesis protein
Rv2453c Involved in metabolism and respiration, associated with non replicating bacteria
Secreted antigen 85A and 85B
Hypotheticall cell wall protein
Rv3804c (85A) (p)
Rv1886c (85B)
(both as peptides
and protein)
Rv0959
Mycolyl transferase activity. Responsible for the high affinity of mycobacteria to
fibronectin
Cell- wall associated protein
Probable lipoprotein LPRJ Rv1690 Contains possible signal sequence and a prokaryotic membrane lipoprotein lipid
attachment site
Secreted ESAT-6 like protein ESXH
(TB10.3)
ESAT-6
Rv3019
Rv3875 (p)
M.tb pathogenicity
Possible glycosyl transferase Rv2957c, Rv2958c
Rv2962c
cellular metabolism and lipid formation, contributes to M.tb survival in macrophages
Possible hemolysin -like protein Rv1085c virulence and adaption
Probable isocitrate dehydrogenase Rv0066c cellular metabolism
Low molecular weight protein
antigen 7 esxH
Rv0288 (TB10.4)
peptides and protein
bacterial virulence
List of M.tb target antigens used for T-cell stimulation. Proteins are designated with (p) unless stated otherwise
Table 2 Results of TST, QTF-GIT, culture and Acid-fast
staining of sputum from patients from Belarus (active
tuberculosis)
ID TST (mm) QTF-GIT Culture AFB
011-1 10 pos pos neg
011-2 16 pos neg neg
011-3 18 pos pos pos
011-4 10 pos pos neg
011-5 neg neg pos pos
021-1 17 neg pos pos
021-2 9 pos pos neg
021-3 20 pos pos neg
021-4 14 neg pos neg
021-5 14 pos pos neg
021-6 14 pos neg neg
021-7 15 pos neg neg
021-8 15 pos pos pos
021-9 13 pos pos neg
021-10 12 neg neg neg
Total positive 14/15 11/15 11/15 4/15
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ticipants were not tested with QTF-GIT.
In vitro long-term IFN-g response to peptide pools
Diluted whole-blood cultures were stimulated with the
panel of M.tb antigens, followed by detection of IFN-g
production in culture supernatants. We identified differ-
ences in the number of responders to specific peptide
pools between the groups (Figure 1). Peptides from
Rv2957 elicited T cell responses in 7/15 (47%) of healthy
individuals, 9/15 (60%) of individuals recovered from TB
and in 4/15 (27%) of patients with TB (adjusted p-value
= 0.39). Rv2958c was recognized by T cells in 8/15
(53%) healthy individuals followed by those recovered
from TB (4/15 = 27%) and TB-patients (3/15 = 20%)
(adjusted p-value = 0.39). 5/15 (33%) of healthy partici-
pants, 6/15 (40%) of TB-recovered and 3/15 (20%) TB-
patients responded to Rv2962c (p-value = 0.71) (Figure
1). The non-adjusted and FDR-adjusted p-values are
summarized in the Additional file 3: Table S3. Rv0447c
(Cyclopropane fatty acyl phospholipid synthase) induced
IFN-g production in 11/15 (73%) individuals recovered
from TB and in 7/15 (47%) TB-patients, in contrast to
healthy individuals (4/15 = 27%, p value 0.046, after
FDR adjustment: p-value = 0.18) (Figure 1).
Most of the individuals in each group responded to
Rv3019 (ESAT-6 like protein) with the strongest IFN-g
production in the group who recovered from TB. In
addition, Rv3347c peptides (PPE-family-protein) were
most commonly recognized by individuals recovered
from TB 8/15 (53%) (Figure 1).
Rv2453c (probable molybdopterin-guanine dinucleotide
biosynthesis), associated with non-replicating bacteria, was
recognized by PBMCs in 7/15 (47%) healthy individuals
and in 10/15 with previous TB (67%). Only 4/15 (27%) of
patients with active TB responded to this antigen (adjusted
p-value = 0.29). The peptide antigens Rv0288 (TB10.4)
and Rv0959 were recognized by most of the Belarusian
participants included in the study (Figure 1).
For comparison, we tested blood from 17 healthy,
non-BCG vaccinated individuals from Sweden for T-cell
reactivity directed against the identical target panel. The
pattern of peptide recognition appears to be broader
among participants from Belarus compared to the Swed-
ish subjects (Figure 2). Yet, T cells from one of the
Swedish participants responded to all antigens tested. Of
note, several subjects from Sweden responded to
Rv0447c peptides (Figure 2). There was a statistical sig-
nificant difference in IFN-g production and in the num-
ber of individuals responding to ESAT-6-like protein
Rv3019 (p = 0.0267) from Belarus as compared to parti-
cipants from Sweden.
IFN-g response to M.tb proteins
Ap a n e lo fM.tb proteins was used to gauge the cellular
immune responses in blood from the cohorts in Belarus
(healthy, previous TB or TB ± individuals) as well as in
Table 3 Results of the TST and QTF-GIT test of healthy
individuals from Belarus and those recovered from TB
TB-recovered Healthy individuals
ID TST
(mm)
QTF-
GIT
ID TST
(mm)
QTF-
GIT
012-6 19 neg 013-11 9 neg
012-7 18 pos 013-12 14 pos
012-8 17 neg 013-13 12 neg
012-9 neg neg 013-14 13 neg
012-10 15 pos 013-15 16 neg
022-1 16 neg 023-1 12 neg
022-2 17 pos 023-2 9 neg
022-3 18 pos 023-3 13 pos
022-4 17 pos 023-4 11 neg
022-5 11 pos 023-5 15 neg
022-6 15 neg 023-6 11 pos
022-7 11 neg 023-7 11 pos
022-8 15 pos 023-8 19 pos
022-9 13 pos 023-9 16 pos
022-10 14 pos 023-10 30 neg
Total
positive
14/15 9/15 Total
positive
15/15 6/15
Figure 1 Visualization of differences in IFN-g production in
response to M.tb peptide pools using heatmaps in individuals
from Belarus. Darker colors (red) represent higher and lighter
colors (white) lower INF-g production. Top panel: Healthy individuals
(n = 15); Middle panel: Individuals recovered from TB (15 =); Bottom
panel: TB+ patients (n = 15) from Belarus. The negative controls and
constitutive IFN-g production is subtracted.
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and 4). T cells from most of the individuals in all three
groups from Belarus responded to the entire protein
panel (Rv3804c, Rv1886c, Rv3875, Rv0288, Rv0754,
Rv0978c and Rv1917) (Figure 3). There was a significant
difference in INF-g production and specific protein
recognition between healthy individuals from Sweden
and in healthy individuals from Belarus (Figure 4). Cells
obtained from individuals from Belarus exhibited higher
IFN-g production and responded more frequently to
antigens Rv3804c (p = 0.0170), Rv1886c (p = 0.0015),
Rv3875 (p = 0.0170), Rv0754c (0.0447) and Rv1917c
(0.0447) as compared to participants from Sweden. Sev-
eral proteins used in this study were recognized by par-
ticipants from Sweden, although the IFN-g production
was lower compared to the healthy individuals from
Belarus (Figure 4).
Candidate M.tb antigens are recognized by polyfunctional
T cells
Most the test antigens listed in Table 1 are also
expressed by BCG and MOTT. At this point, we did
not have access to PBMCs from individuals (i.e. infants)
prior to BCG vaccination from Minsk, or as longitudin-
ally sampled PBMCs reflecting the sequence of multiple
BCG vaccinations. Although we could not control the
exposure to MOTT in non-human primates (NHPs), we
resorted to the analysis of more detailed cellular
immune responses in PBMCs from NHP prior to and
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functional T cells responding to M.tb test antigens. In
an attempt to understand the immune responses to
selected antigens seen in the study population, we per-
formed measurements of intracellular IFN-g, TNF-a and
IL-2 production in CD4+ and CD8+ T cells from NHP
in response to peptides from Rv0447c, and a cocktail
from Rv2957/Rv2958c peptides using cryo-preserved
PBMCs, previously obtained from NHPs included in a
vaccine study [24]. As shown in Figure 5, PBMCs from
NHPs vaccinated with BCG exhibited both CD4+ T
cells and CD8+ T cells producing IL-2, IFN-g and TNF-
a in response to stimulation with Rv0447c (Cyclopro-
pane fatty-acyl phospholipid synthase) and to Rv2957/
Rv2958c (Glycosyltransferase). Cytokine production was
higher after BCG vaccination in both CD4+ and CD8+
T cells (Additional file 4: Figure S1).
Discussion
We used pools of several MHC class II-binding peptides
from M.tb for their ability to stimulate IFN-g production
in vitro using whole blood from Belarusian individuals
with a history of previous TB, patients with active pul-
monary TB and healthy individuals (most likely TB
exposed). In addition, 17 non-BCG vaccinated healthy
individuals from Sweden were also included in the study.
The selected peptides have shown to be expressed in
replicating bacteria (Rv0477c, Rv2940c, Rv1690, Rv1085c,
Rv1886, Rv2962c, Rv2958c, Rv2957c), non-replicating
bacteria (Rv2453c, yet also Rv0477c, Rv2940c) and are
suggested to be able to differentiate between M.tb,
MOTT and BCG (Rv3019, Rv0066c, Rv3347c). Some
peptide pools (glycosyl transferase) are more frequently
recognized by T cells from healthy individuals as com-
pared to TB+ patients suggesting that these were sensi-
tized to mycobacteria. In addition, individuals recovered
from TB recognized a broader panel of peptide pools
compared to the other two groups (healthy or TB+)
which indicates that the responses to M.tb specific anti-
gens apparently persist in individuals who had recovered
from pulmonary TB (i.e. long-term memory cellular
responses). Of note, the analysis presented in the current
report is based on IFN-g production in PBMCs. The
simultaneous measurement of additional chemokines/
cytokines, including CXCL10 and IL-10 will most likely
increase the discriminatory power and biological value of
immunological readouts to M.tb antigens [26].
One of the strategies in developing new diagnostic
methods improving TB vaccine design involves the iden-
tification of biomarkers for protection and novel T cell
targets. Of particular interest is glycosyltransferase,
involved in cellular metabolism and lipid formation. It
has been shown that glycosyltransferase genes contri-
bute to M.tb survival in macrophages [27]. Interestingly,
the peptide pools from Rv2957c, Rv2958 and Rv2962c
were more commonly recognized by T cells from
healthy (most likely TB exposed) individuals as com-
pared to TB-patients (Figure 1, see Additional file 3:
Table S3), yet larger clinically well defined cohorts are
needed in order to provide biologically relevant biomar-
kers to study M.tb immune responses and to test for
novel M.tb vaccine targets.
Other peptide pools from M.tb proteins involved in
lipid formation and synthesis of long fatty acids,
Rv0477c (Cyclopropane fatty acyl phospholipid synthase)
induced IFN-g production in the majority of PBMCs
from individuals suffering from TB (73%) (Figure 1).
Since mycolic acids represent a major constituent of the
mycobacterial cell wall complex, they provide the first
line of defense against potentially lethal environmental
conditions. Slow growing pathogenic mycobacteria such
as M.tb modify their mycolic acids by cyclopropanation
which is a common membrane modification in bacteria
and plants [28,29] and essential for viability, drug resis-
tance and cell wall integrity [30] playing an important
role in M.tb pathogenesis [31,32].
Chemical inhibition of mycolic acid methyltransferases
has shown to be lethal to M.tb and causes alterations in
Figure 5 Strong polyfunctional CD4+ and CD8+ T cell
responses directed against Rv0477c M.tb target peptides.
PMBCs were obtained after BCG vaccination and tested by ICS for
IFN-g, TNF-a and IL-2 production in CD4+ and CD8+ T cells. First,
cells were gated on site and forward scatter, followed by gating on
CD3+ events and CD4+ versus CD8+ T-cells. Responding T-cells
were first tested for IFN-g production, followed by IL-2 versus TNF-a
production in the IFN- g + and IFN-g - T cell populations. Controls
included stimulation with medium or with PMA/ionomycin (data
not shown).
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Thus, Rv0477c may present an interesting target for
development of new antibiotics against M.tb. Detectable
cellular responses to Rv0477c, although limited, were
also found in PBMCs from healthy Swedish controls. It
is possible that immune recognition of this antigen is
partially primed by exposure to or infection with
MOTT since mycolic fatty acids are also present in
MOTT. Cyclopropane fatty acids are also present in
many other bacterial species expressed in stationary
phase cells, including E.coli [29]; structural homologies
m a yb er e s p o n s i b l ef o rc r o s s -reactive T-cell responses.
Of interest, a recent report showed that mutations in
the rpoS-regulated genes in E.coli ( i . e .c f a ,c y c l o p r o p a n e
fatty acid synthetase and osmB, outer membrane lipo-
protein) are significantly higher sensitive to (oxidative)
stress and impaired in membrane repair mechanism
[33].
This notion is supported by our observation that con-
stitutive and antigen-specific IFN-g, IL-2 and TNFa pro-
duction can be detected by ICS in CD4+ and CD8+ T-
cells from NHPs prior to BCG vaccination, yet that
BCG lead to a strong expansion of polyfunctional T
cells. Future experiments, using T cells from animals
housed under sterile conditions may show the contribu-
tion of MOTT and their role in providing an immuno-
logical matrix which can be boosted by TB vaccination
strategies.
While there are no precisely defined correlates of pro-
tection against mycobacterial infection at present, IFN-g
producing Th1 cells are believed to be essential in pro-
tection against TB [34,35]. In this study we focused on
INF-g and showed that there is a difference in IFN-g
production between the study groups. At this point, we
cannot determine if the IFN-g production observed in
this study was due several BCG vaccinations, due to
contact with M.tb in Belarus, or - mutually not exclusive
- to related target structures present in other bacterial
species.
Rv3804c, Rv1886c and Rv0288 present in M.tb and
BCG have been extensively used in different vaccine
trials. In general, Rv3804c was most commonly recog-
nized in each group tested. Also several Swedish sub-
jects responded to this antigen. Furthermore, IFN-g
production was higher in response to proteins compared
to the peptides (Figures 1, 2, 3, 4). Differences may be
due to i) peptide instability, ii) differential antigen pro-
cessing and presentation and iii) the fact that the pep-
tide pools did not cover the entire protein antigen.
These differences may also, in part, explain the strong
recognition of the recombinant proteins from the PPE
family members Rv0978, Rv0754 and Rv1971c in
patients with TB [18-21] in PBMCs from individuals
who recovered from TB and also in healthy individuals
with no record with TB (yet most likely exposed, since
these individuals are health care workers) (Figure 2).
The same was true for target recognition from T cells
obtained from individuals (TST-, non-BCG vaccinated)
from Sweden (Figure 4). These antigens have been
reported to provide epitopes differentiating humoral
immune responses in individuals with TB. Yet more
detailed experiments showed that Rv0978 and Rv0754
recognize TLR2 and induce maturation and activation
of human DCs [19]. They enhance the ability of DCs to
stimulate CD4+ T-cell responses and activate the ERK1/
2, p38 MAPK, and NF-kappaB signaling pathways in
D C sa n dm a yb ei n s t r u m e n t a lt os h a p et h eq u a l i t yo f
the innate cellular immune response in exposure to
mycobacterial species. This may, in part, explain the
strong IFN-g production in response to the M.tb pro-
teins; corresponding peptide cocktails may not provide
these signals leading to DC maturation.
Differences in M.tb antigen recognition may be asso-
ciated with i) the ‘genetic makeup’ of the test popula-
tion, ii) alternate M.tb target molecules in circulating
strains, iii) extent of TB disease, previous exposures to
M.tb and iv) cross-reactive T-cell responses directed
against closely related targets from other bacterial spe-
cies: only a clinically well defined study population,
along with genetic M.tb strain [36,37] and host immu-
nological marker analysis will aid to visualize a more
realistic pattern of anti-M.tb directed immune
responses.
We also compared in the current study the cellular
immune responses to M.tb-antigens in healthy indivi-
duals from Sweden and from Belarus. The number of
responders to each antigen was higher and the IFN-g
production was stronger in the group of individuals
from Belarus. The difference seen between the groups is
most likely a reflection of the environment since Sweden
i sal o wT Be n d e m i cc o u n t r yi nc o n t r a s tt oB e l a r u s
where TB burden is high [2]. Furthermore, individuals
from Belarus received two to three BCG vaccinations,
which may alter the immune responses to M.tb proteins.
None of the Swedish controls were BCG vaccinated and
had no identified risk of exposure to TB.
TST is the primary method for diagnosis of latent TB
infection in many countries but is not able to distin-
guish between BCG vaccination and reactions caused by
M.tb infection itself. In the present study, viable M.tb
bacilli could be detected in some patients with a positive
AFS, while the immunological assays used (TST and
QFT-GIT) provided negative results (Table 2). In three
culture confirmed TB cases, the IGRA tested negative.
All the TST positive individuals were positive for QFT-
GIT within TB-positive cases. The discrepancy seen
between the immunological and bacteriological assays is
most likely due to not fully functional T cells from
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HLA backgrounds in response to selected peptides in
this study. Although most of the people in Belarus are
Caucasian, it is still likely that some individuals may not
have responded to selected target peptide pools.
Conclusion
We show that PBMCs from healthy individuals from
Belarus and those recovered from TB recognized a
broader panel of M.tb- a n t i g e n sa sc o m p a r e dt oT B -
patients, defined by IFN-g production. Individual M.tb
antigens were strongly recognized by polyfunctional T
cells in PBMCs from NHPs housed in a controlled
environment after BCG vaccination. The data show that
screening with selected peptide pools aids to identify
biologically relevant M.tb targets, e.g. cyclopropane
fatty-acid synthase and glycosyl transferase, which may
have potential as targets for TB-diagnosis and to mea-
sure BCG vaccine take.
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Additional file 1: Table S1. Detailed information concerning TB patients
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